|1.||Zhang, Wei: 14 articles (01/2013 - 01/2002)|
|2.||Fuller, Gregory N: 11 articles (02/2012 - 01/2002)|
|3.||Holly, Jeff M P: 8 articles (05/2013 - 09/2006)|
|4.||Gunnell, David: 7 articles (01/2013 - 09/2006)|
|5.||Martin, Richard M: 7 articles (01/2013 - 09/2006)|
|6.||Russo, Vincenzo C: 6 articles (10/2015 - 06/2011)|
|7.||Hoeflich, Andreas: 6 articles (10/2015 - 11/2002)|
|8.||Disis, Mary L: 6 articles (05/2014 - 01/2008)|
|9.||Frystyk, Jan: 6 articles (04/2014 - 08/2006)|
|10.||Rowlands, Mari-Anne: 6 articles (01/2013 - 05/2009)|
01/01/2001 - "In a follow-up study, plasma IGFBP-2 concentration remained stable in patients with complete remission or stabilized disease and was a late marker of tumor progression in patients with progressive metastatic disease. "
01/01/2001 - "Analysis of individual IGFBP-2 concentrations showed that five patients (17.8%) with metastatic tumors had normal IGFBP-2 levels and two patients (13.3%) in complete remission had high plasma IGFBP-2 levels. "
01/01/2001 - "There was no significant difference in plasma IGFBP-2 concentration between healthy controls and patients with complete remission or localized tumors. "
08/01/1994 - "Serum IGFBP-2 levels were increased in patients with solid peripheral tumors (P < 0.05), whereas patients in complete remission had normal serum IGFBP-2 levels. "
01/01/2008 - "Furthermore, significantly greater levels of IGFBP-2 antibody immunity were found in cancer patients compared to normal controls (p = 0.008). "
|2.||Neoplasm Metastasis (Metastasis)
07/04/2013 - "Overexpression of IGFBP-2 in CRC cells lacking L1-enhanced cell proliferation (in the absence of serum), cell motility, tumorigenesis and induced liver metastasis, similar to L1 overexpression. "
01/01/2010 - "In particular, increased levels of IGFBP-2 expression are associated with advanced PCa, bone metastasis, and the development of castrate resistant PCa. "
11/01/2000 - "We tested the potential tumour marker characteristics of IGFBP-2 SDS against three endpoints: metastasis alone; local pelvic recurrence alone; and metastasis and recurrence combined. "
06/01/2014 - "Is insulin-like growth factor binding protein 2 associated with metastasis in lung cancer?"
10/21/2006 - "Expression of IGFBP-2 in gastric carcinoma with lymph node metastasis was higher than that without lymph node metastasis (P < 0.01). "
05/01/2015 - "Overexpression of IGFBP-2 in transgenic mice prevents obesity, but depot-specific effects of IGFBP-2 on adipo/lipogenesis are unknown. "
06/01/2014 - "Overexpression of IGFBP-2 protects against obesity and type 2 diabetes. "
07/06/2012 - "Although IGFBP-2 derives mostly from the liver, recent evidence in mice and humans indicate that aging and obesity are associated with altered IGFBP-2 levels in white adipocytes. "
06/01/2011 - "Within this manuscript, we explore the associations between IGFBP-2 and obesity with a particular emphasis on how an increased understanding of the role of IGFBP-2 in metabolism may lead to improvements in the prevention and treatment of childhood obesity."
06/01/2011 - "IGFBP-2 may be integrally involved in the molecular processes that govern the development of obesity and subsequent weight-related disease. "
|4.||Urinary Bladder Neoplasms (Bladder Cancer)
02/01/2005 - "These findings suggest that overexpression of IGFBP-2 induces an increase in MMP-2 production, resulting in the enhanced metastatic potential of bladder cancer."
02/01/2005 - "The objective of this study was to investigate the effect of IGFBP-2 overexpression in human bladder cancer KoTCC-1 cells on their phenotype associated with tumor progression. "
02/01/2005 - "Overexpression of insulin-like growth factor binding protein-2 (IGFBP-2) has been shown to be associated with tumor progression in several human malignant tumors; however, the significance of IGFBP-2 expression in bladder cancer remains poorly defined. "
08/01/2015 - "In conclusion, inhibition of IGFBP-2 improved the sensitivity of bladder cancer cells to cisplatin by elevating the expression of maspin."
08/01/2015 - "Inhibition of IGFBP-2 improves the sensitivity of bladder cancer cells to cisplatin via upregulating the expression of maspin."
03/01/1995 - "More moderate undernutrition (80% of requirements) did not affect circulating IGFBP-2 but did alter the response of IGFBP-2 to bST. "
07/01/1991 - "Malnutrition caused a significant reduction in both serum IGF-I and -II after day 12 PP, while causing an elevation in serum IGFBP-2. "
01/01/2001 - "Nutritional status was evaluated by determining IGF-I levels and was found to be normal in 16 patients (61.5%) with high IGFBP-2 levels, suggesting that malnutrition was not responsible for the high IGFBP-2 concentrations in these patients. "
07/01/1991 - "Malnutrition caused a delay in the development shift from IGFBP-2 to IGFBP-3, which normally occurs between day 15 and 19 in the rat. "
12/01/2001 - "In spite of the significant changes of IGF-I, IGFBP-2, total IGFBP-3 and IGFBP-3 (29 kDa proteolytic fragment) after rhGH administration to patients with malnutrition, maintained on parenteral nutrition, the increase of nitrogen balance was seen only in patients who decreased their IGFBP-1 and increased bioavailable IGF-I as reflected by measurement of fIGF-I. The levels of IGFBP-1 may provide a useful marker of IGF-I bioavailability in monitoring the efficiency of the rhGH therapy in malnourished patients."
|2.||Insulin-Like Growth Factor I (IGF-1)
|3.||Insulin-Like Growth Factor Binding Protein 3
|4.||Insulin-Like Growth Factor II (Somatomedin A)
|9.||Insulin-Like Growth Factor Binding Proteins
|10.||Insulin-Like Growth Factor Binding Protein 1
|1.||Drug Therapy (Chemotherapy)
|2.||Heterologous Transplantation (Xenotransplantation)